Continuous Hyperthermic Peritoneal Perfusion Therapy for Gastric Cancer

Kenji Ohkubo

The Second Department of Surgery, Yokohama City University, School of Medicine (Director:Prof. Hiroshi Shimada)

To elucidate the effect of continuous hyperthermic peritoneal perfusion (CHPP), 47 patients with gastric cancer in stage IVb without liver metastasis were evaluated using therapeutic parament such as adjuvant chemotherapy and clinicopathological paraments such as lymph node metastasis, peritoneal dissemination, p53 expression, vimentin expression and growth index (=%Ki67 index/%apoptosis index). Survival in patients treated by CHPP have a higher tendency than that in patients treated by non-CHPP with adjuvant chemotherapy, without peritoneal dissemination and with p53 expression less than 70% (Cox-Mantel test P<0.05). But there was no significant difference of survival between in CHPP and in non-CHPP without adjuvant chemotherapy, with peritoneal dissemination and with p53 expression more than 70%. According to multivariate analysis, peritoneal dissmination and p53 expression were determinant prognostic of gastric cancer, but CHPP was not.

Key words
gastric cancer, continuous hyperthermic peritoneal perfusion therapy, p53

Reprint requests
Kenji Ohkubo The Second Department of Surgery, Yokohama City University School of Medicine 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004 JAPAN

Accepted
January 27, 1999

To read the PDF file you will need Abobe Reader installed on your computer.